Nabriva Therapeutics plc (NBRV) stock rallied today after the news appeared that Lefamulin received approval in Taiwan for Pneumonia treatment. NBRV stock price saw a push of 7.40% to reach $1.16 a share at the time of this writing. The stock was gloomy in the previous trade and went down by 2.70% at closing with a $1.08 per share price.

Nabriva Therapeutics plc is the biopharmaceutical stock that develops and commercializes anti-infective agents for the treatment of serious infections. Its main products are XENLETA, which treats community-acquired pneumonia, and SIVEXTRO that treats bacterial skin infections. Let’s dig in to explore the recent events.

Recent News of NBRV stock:

Nabriva partner, Sumitomo Pharmaceuticals (Suzhou) Co., Ltd has received the approval for marketing Lefamulin, in Taiwan to treat adults suffering from community-acquired pneumonia. Lefamulin represents oral and intravenous formulations of XENLETA®.

Back in May 2021, NBRV stock signed an agreement with Sumitomo Pharmaceuticals for the development and commercialization rights for Lefamulin in China. Sumitomo Pharmaceuticals is an affiliate of Sumitomo Dainippon Pharma. NBRV stock has not decided the launching time of XENLETA® in Taiwan so far.

Inducement Grants by NBRV stock:

At the start of this month, Nabriva granted non-statutory stock options to its three newly hired employees as an inducement grant to purchase an aggregate of 32,130 shares of NBRV stock. The stock options had an exercise price of $1.06 per share. Each stock option has a 10-year term and vest for over four years. NBRV stock’s compensation committee had approved the stock option.

Financial View of NBRV stock:

According to Nabriva’s second-quarter 2021 financial results which is released on August 5, 2021.

• NBRV stock generated $8.2 million in three months ended June 30, 2021, a $7.8 million increase from the prior year same quarter. The increase in revenue was mainly due to a $7.0 million increase in product revenue.
• Cost of product sales reached $3.6 million in the recently reported quarter due to the launch of SIVEXTRO NDC on April 12, 2021.
• Nabriva spent $3.2 million in research and development expenses, $0.7 million less as compared to the same tenure of the prior-year quarter.
• Selling, general and administrative expenses jumped by $2.1 million from prior-year same quarter to $10.7 million in Q2,2021.
• Nabriva reported an $11.8 million net loss for Q2, 2021, $3.6 million less than the same prior-year period.
• By the end of June 2021, NBRV stock had $61.3 million in cash and cash equivalents.

Wrap Up:

Investors are responding positively to the recent announcement of Nabriva stock. The stock has not progressed in terms of its per-share price in 2021 as it lost 57.14% year to date.